By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > General > Sulfasalazine

Sulfasalazine

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|637 words

What is Sulfasalazine?

Sulfasalazine is a medication that belongs to a class of drugs called disease-modifying antirheumatic drugs (DMARDs) and aminosalicylates. It combines sulfapyridine, an antibiotic, with 5-aminosalicylic acid (mesalamine), an anti-inflammatory compound. Sulfasalazine is primarily used to treat inflammatory bowel diseases like ulcerative colitis and rheumatoid arthritis.

Uses

Sulfasalazine has several established medical uses:

Ulcerative colitis: It helps reduce inflammation in the colon and rectum, controlling symptoms and maintaining remission in patients with mild to moderate disease.

Rheumatoid arthritis: As a DMARD, it helps slow joint damage and reduce inflammation, pain, and stiffness in patients who haven’t responded adequately to other treatments.

Submit Your Paper
GMJ_Submit_Banner

Crohn’s disease: While less commonly used than for ulcerative colitis, it may help manage inflammation in some patients with mild disease affecting the colon.

Juvenile idiopathic arthritis: It’s sometimes prescribed for children and adolescents with certain forms of arthritis when other treatments are insufficient.

Ankylosing spondylitis: In some cases, it may help reduce inflammation and symptoms in this form of inflammatory arthritis affecting the spine.

How it works

Sulfasalazine works through its active metabolite, 5-aminosalicylic acid (5-ASA), which is released when bacteria in the colon break down the drug. The 5-ASA component reduces inflammation by inhibiting the production of inflammatory substances like prostaglandins and leukotrienes in the intestinal wall and joints. The exact mechanism in rheumatoid arthritis is not fully understood, but it appears to suppress immune system activity and reduce inflammatory processes.

Side effects

Common side effects include:

  • Nausea and vomiting
  • Loss of appetite
  • Headache
  • Dizziness
  • Abdominal pain
  • Diarrhea
  • Skin rash
  • Orange-yellow discoloration of urine and skin

Serious side effects to watch for:

  • Severe allergic reactions with difficulty breathing or swelling
  • Blood disorders including low white blood cell count or anemia
  • Liver problems with yellowing of skin or eyes
  • Severe skin reactions including Stevens-Johnson syndrome
  • Kidney problems with changes in urination

Warnings and precautions

Patients with known allergies to sulfa drugs or salicylates should avoid sulfasalazine due to risk of severe allergic reactions. The medication can reduce sperm count and motility in men, though this effect is usually reversible when the drug is stopped. Regular blood tests are necessary to monitor for blood cell count changes and liver function abnormalities. Patients with kidney or liver disease require careful monitoring and possible dose adjustments. The drug is classified as pregnancy category B, meaning it’s generally considered safe during pregnancy, but should only be used when clearly needed and under medical supervision.

Interactions

Warfarin and other blood thinners: Sulfasalazine may increase bleeding risk by enhancing anticoagulant effects.

Methotrexate: Concurrent use may increase methotrexate toxicity by reducing its elimination from the body.

Digoxin: Sulfasalazine can reduce digoxin absorption, potentially decreasing its effectiveness.

Folic acid supplements: Sulfasalazine may interfere with folic acid absorption, and supplementation is often recommended.

Iron supplements: The medication can reduce iron absorption when taken together.

Azathioprine and 6-mercaptopurine: Combination may increase risk of blood disorders.

Live vaccines: Should be avoided due to potential reduced immune response.

Cyclosporine: Sulfasalazine may reduce cyclosporine levels, requiring monitoring.

Check interactions with the GMJ Interaction Checker

Dosage

For ulcerative colitis, the typical adult starting dose is 1-2 grams daily, divided into multiple doses, gradually increased to a maintenance dose of 2-4 grams daily as tolerated. For rheumatoid arthritis, treatment usually begins with 500 mg daily, increased gradually over several weeks to a target dose of 2-3 grams daily, divided into two doses. The medication should be taken with food to minimize stomach upset. Dosage adjustments may be necessary based on patient response, tolerance, and kidney function. Healthcare providers should always determine the appropriate dosage based on individual patient factors and medical condition severity.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Sulfasalazine." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/sulfasalazine/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
FDA’s Pazdur Calls for Agency Restructuring Amid China Competition and Internal Upheaval

FDA's Rick Pazdur calls for fundamental agency restructuring following internal disruption, citing…

Revolution Medicines Ships Experimental Pancreatic Cancer Drug Under Early Access

Revolution Medicines begins expanded access program for daraxonrasib targeting KRAS G12C mutations.…

NHS Patient Watchdog Abolition Sparks Concerns Over Health Service Accountability

Local councils warn that government plans to abolish NHS patient watchdogs will…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Zinc supplements

By
Prof. Giorgi Pkhakadze
02/06/2026

Turmeric/Curcumin

By
Prof. Giorgi Pkhakadze
02/06/2026

Iodine supplements

By
Prof. Giorgi Pkhakadze
02/06/2026

Ivabradine

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up